Order SE, Donahue VC, Knapp RC. Immunotherapy of ovarian carcinoma: An experimental model. Cancer 32(3): 573-579; 1973.
Order SE, Kirkman R, Knapp RC. Serologic immunotherapy: Results and probable mechanisms of action. Cancer 34(1): 175-183; 1974.
Knapp RC, Berkowitz RS. Corynebacterium parvum as an immunotherapeutic agent in an ovarian cancer model. American Journal of Obstetrics & Gynecology 128(7): 782-786; 1977.
Bast RC Jr., Knapp RC, Mitchell AK, et al. Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. Journal of Immunology 123(5): 1945-1951; 1979.
Bast RC Jr, Berek JS, Obrist R, et al. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Research 43(3): 1395-1401; 1983.
Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity Nature 257(5517): 495-497; 1975.
Bast RC Jr, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. Journal of Clinical Investigation 68(5): 1331-1337; 1981.
Bast RC Jr, Klug TL, St. John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New England Journal of Medicine 309(15): 883-887; 1983.
Davis HM, Zurawski VR Jr, Bast RC Jr, et al. Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Research 46(12 pt 1): 6143-6148; 1986.
Campbell IG, Nicolai HM, Foulkes WD, et al. A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. Human Molecular Genetics 3(4): 589-594; 1994.
Nustad K, Bast RC Jr, O'Brien TJ, et al. Specificity and affinity of 26 monoclonal antibodies against the CA125-related antigen. Report from the ISOBM TD1 workshop. Tumor Biology 17(4): 196-219; 1996.
Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: A review of the literature. Human Reproduction 4(1):1-12; 1989.
Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. Journal of Clinical Oncology 14(5): 1545-51; 1996.
Hunter VJ, Daly L, Helms M, et al. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. American Journal of Obstetrics & Gynecology 163(4 pt 1): 1164-1167; 1990.
Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. British Journal of Obstetrics & Gynaecology 97(10): 922-929; 1990.
Mok CH, Tsao SW, Knapp RC, et al. Unifocal origin of advanced human epithelial ovarian cancer. Cancer Research 52(18): 5119-5122; 1992.
Jacobs IJ, Kohler MF, Wiseman R, et al. Clonal origin of epithelial ovarian cancer: analysis by loss of heterozygosity, p53 mutation, and X chromosome inactivation. Journal of the National Cancer Institute 84(23): 1793-1798; 1992.
Karlan BY, Platt LD. The current status of ultrasound and color doppler imaging in screening for ovarian cancer. Gynecologic Oncology 55(3 pt 2): S28-S33; 1994.
Bast RC Jr, Siegal FP, Runowicz C, et al. Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecologic Oncology 22(1):115-120; 1985.
Woolas R, Xu FJ, Jacobs I, et al. Case Report: Elevated serum levels of macrophage colony stimulating factor and OVX1 11 months prior to the diagnosis of stage IC ovarian cancer. International Journal of Gynecological Cancer 6: 156-158; 1996.
Zurawski VR Jr., Orjaseter H, Andersen A, et al. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. International Journal of Cancer 42(5): 677- 680, 1988.
Jacobs I, Stabile I, Bridges J, et al. Multimodal approach to screening for ovarian cancer. Lancet 1(8580): 268-271; 1988.
Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. British Medical Journal 306(6884): 1030-1034; 1993.
Zurawski VR Jr, Sjovall K, Schoenfeld DA,et al. Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecologic Oncology 36(3): 299-305; 1990.
Einhorn N, Sjovall K, Knapp RC,et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstetrics & Gynecology 80(1): 14-18; 1992.
Skates SJ, Xu F-J, Yu Y-H, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 76(10 Suppl): 2004-2010; 1995.
Xu FJ, Ramakrishnan S, Daly L, et al. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. American Journal of Obstetrics & Gynecology 165(5 pt 1): 1356-1362; 1991.
Xu FJ, Yu Y-A, Daly L, et al. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. Journal of Clinical Oncology 11(8): 1506-1510; 1993.
Woolas RP, Xu FJ, Jacobs IJ, et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. Journal of the National Cancer Institute 85(21): 1748-1751; 1993.
Urban N, Drescher C, Etzioni R, et al. Use of a stochastic simulator model to identify an efficient protocol for ovarian cancer screening. Controlled Clinical Trials (In press).
Fayed S, Wu S, Lidor Y, et al. Identification and purification of a novel 30 kd ovarian carcinoma associated protein. (In press).
Yu Y-H et al. [Unpublished data.]
Woolas RP, Conaway MR, Xu F-J, et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecologic Oncology 59(1): 111-116; 1995.